


Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed [Claims]

1.(Original) A compound of formula (I) or a pharmaceutically acceptable salt



thereof:

wherein:

R₁ is hydrogen, hydroxy, fluoro, chloro, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, C₁₋₆alkoxy or haloC₁₋₆alkoxy;

m is 0 when $\text{C}=\text{C}$ is a double bond and m is 1 when $\text{C}-\text{C}$ is a single bond;

R₂ is hydrogen, halogen, cyano, nitro, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, C₁₋₆alkylthio, amino, mono- or di-C₁₋₆alkylamino or an N-linked 4 to 7 membered heterocyclic group;

X is $-(\text{CH}_2-\text{CH}_2)-$, $-(\text{CH}=\text{CH})-$, $-(\text{CH}_2)_3-$, $-\text{C}(\text{CH}_3)_2-$, $-(\text{CH}=\text{CH}-\text{CH}_2)-$, $-(\text{CH}_2-\text{CH}=\text{CH})-$ or a group $-(\text{CHR}_5)-$ wherein R₅ is hydrogen, halogen, hydroxy, cyano, nitro, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy or C₁₋₆alkylthio;

R₃ is halogen, cyano, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, C₁₋₆alkoxy, C₁₋₆alkylthio, hydroxy, amino, mono- or di-C₁₋₆alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC₁₋₆alkyl, haloC₁₋₆alkoxy, aryl, arylC₁₋₆alkyl, arylC₁₋₆alkyloxy, arylC₁₋₆alkylthio or COOR₆, CONR₇R₈ or COR₉ wherein R₆, R₇, R₈ and R₉ are independently hydrogen or C₁₋₆alkyl;

p is 0, 1 or 2 or 3;

R₄ is hydrogen, halogen, hydroxy, cyano, nitro, C₁₋₆alkyl, C₁₋₆alkanoyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkyloxy, haloC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy,

C₁-6alkylthio, amino, mono- or di-C₁-6alkylamino or an N-linked 4 to 7 membered heterocyclic group;

Y is oxygen, sulfur, -CH₂- or NR₁₀ wherein R₁₀ is hydrogen or C₁-6alkyl;


D is a single bond, -CH₂-, -(CH₂)₂- or -CH=CH-; and

Z is an optionally substituted C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, an optionally substituted N-linked 4 to 7 membered heterocyclic group, or Z is -NR₁₁R₁₂ where R₁₁ and R₁₂ are independently hydrogen or C₁-6alkyl.

2. (Original) A compound as claimed in claim 1, wherein X is -CH₂-.

3. (Presently Amended) A compound as claimed in claim 1 [or claim 2], wherein when \equiv is a single bond, R₁ is hydrogen, hydroxy or C₁-6alkoxy.

4. (Presently Amended) A compound as claimed in claim 1 having the following formula (Ia):



wherein R₃, p, R₄, Y, D, Z, \equiv are as defined in claim 1 and X₁ is -CH₂- or -HC(OH)-.

5. (Presently Amended) A compound as claimed in [any of claims 1-4] claim 1, wherein p is 1 or 2 and R₃ is/are halogen, particularly chloro or fluoro, attached at the 3 or the 3,4-positions of the phenyl ring.

6. (Presently Amended) A compound as claimed in [any of claims 1-5] claim 1, wherein R₄ is C₁-6alkoxy (particularly methoxy), OCF₃, halogen or cyano.

7. (Presently Amended) A compound as claimed in [any of claims 1-6] claim 1 wherein D is -CH₂-.

8. (Presently Amended) A compound as claimed in [any of claims 1-7] claim 1, wherein Y is oxygen.

9. (Presently Amended) A compound as claimed in [any of claims 1-8] claim 1, wherein Z is an optionally substituted N-linked 4 to 7 membered heterocyclic group.

10. (Presently Amended) A compound as claimed in claim 9, wherein Z is piperidyl.

11. (Presently Amended) A compound as claimed in claim 1 which is:

3-(3,4-Dichloro-phenyl)-3-hydroxy-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one;
3-(3,4-Dichloro-phenyl)-3-hydroxy-1-[4-methoxy-3-(2-morpholin-4-yl-ethoxy)-phenyl]-pyrrolidin-2-one;
3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one;
1-[4-Chloro-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-(3,4-dichloro-phenyl)-pyrrolidin-2-one;
1-[4-Chloro-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-(3,4-dichloro-phenyl)-3-hydroxy-pyrrolidin-2-one;
3-(3,4-Dichloro-phenyl)-1-(4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl)-pyrrolidin-2-one;
3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrol-2-one;
3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-morpholin-4-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrol-2-one;
1-[4-Chloro-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-(3,4-dichloro-phenyl)-1,5-dihydro-pyrrol-2-one;
3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrol-2-one;

3-(3-Fluoro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrol-2-one;

3-(3,4-Dichloro-phenyl)-1-(-3-[2-(4,4-difluoro-piperidin-1-yl)-ethoxy]-4-methoxy-phenyl)-1,5-dihydro-pyrrol-2-one;

3-(3-Fluoro-phenyl)-5-hydroxy-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one;

1-[4-Chloro-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-(3,4-dichloro-phenyl)-5-hydroxy-pyrrolidin-2-one;

3-(3,4-Dichloro-phenyl)-1-(-3-[2-(4,4-difluoro-piperidin-1-yl)-ethoxy]-4-methoxy-phenyl)-5-hydroxy-pyrrolidin-2-one;

3-(3-Fluoro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one;

3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one;

3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3-methyl-pyrrolidin-2-one hydrochloride salt;

3-(3-Chloro-phenyl)-1-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-1,5-dihydro-pyrrol-2-one hydrochloride salt;

3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-3,4-dihydro-1H-pyridin-2-one;

3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-piperidin-2-one;

3-(3,4-Dichloro-phenyl)-1-(4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl)-3,4-dihydro-pyrrol-2-one;

3-(3,4-Dichloro-phenyl)-1-(4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl)-4-methyl-1,5-dihydro-pyrrol-2-one;

3-(4-Chloro-phenyl)-1-(4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl)-3,4-dihydro-pyrrol-2-one;

3-(4-Chloro-phenyl)-1-(4-methoxy-3-[2-piperidin-1-yl)-ethoxy]-phenyl)-3,4-dihydro-pyrrol-2-one;

3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(piperidin-3-ylmethoxy)-phenyl]-pyrrolidin-one;

3-(3,4-Dichloro-phenyl)-1-[4-methoxy-3-(1-methyl-piperidin-3-ylmethoxy)-phenyl]-pyrrolidin-one;

N-{4-[3-(3,4-dichlorophenyl)-2-oxo-2,5-dihydro-1*H*-pyrrol-1-yl]-2-[2-(1-piperidinyl)ethoxy]phenyl}acetamide;
N-{4-[3-(3,4-dichlorophenyl)-2-oxo-pyrrolidin-1-yl]-2-[2-(1-piperidinyl)ethoxy]phenyl}acetamide;
3-(3,4-Dichloro-phenyl)-1-{4-methoxy-3-[2-(4-methyl)-piperidin-1-yl-ethoxy]-phenyl}-3-methyl-pyrrolidin-2-one;
3-(3-Chloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one;
3-(3-Trifluoromethyl-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one;
3-(3-Trifluoromethyl-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrol-2-one;
3-(3-Chloro-phenyl)-5-methoxy-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one;
3-(3-Chloro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrol-2-one;
3-(4-Fluoro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-1,5-dihydro-pyrrol-2-one;
3-(4-Fluoro-phenyl)-1-[4-methoxy-3-(2-piperidin-1-yl-ethoxy)-phenyl]-pyrrolidin-2-one;
1-{4-Methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-3-(4-methyl-phenyl)-1,5-dihydro-pyrrol-2-one;
1-{4-Methoxy-3-[2-(piperidin-1-yl)-ethoxy]-phenyl}-3-(4-methyl-phenyl)-1,5-dihydro-pyrrol-2-one;
3-(4-Bromo-phenyl)-1-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-1,5-dihydro-pyrrol-2-one;
1-{4-Methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-3-(4-trifluoromethyl-phenyl)-1,5-dihydro-pyrrol-2-one;
3-(2-Chloro-phenyl)-1-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-1,5-dihydro-pyrrol-2-one;
3-(3,4-Dichloro-phenyl)-3-hydroxy-1-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-pyrrolidin-2-one;
3-(3,4-Dichloro-phenyl)-3-fluoro-1-{4-methoxy-3-[2-(4-methyl-piperidin-1-yl)-ethoxy]-phenyl}-pyrrolidin-2-one;


3-(3,4-Dichloro-phenyl)-1-{4-methoxy-3-[(1-methyl-pyrrolidin-2-yl)-methoxy]-phenyl}-pyrrolidin-2-one;

3-(3,4-Dichloro-phenyl)-1-{4-methoxy-3-[(1-methyl-pyrrolidin-2-yl)-methoxy]-phenyl}-3,4-dihydro-pyrrol-2-one;

or a pharmaceutically acceptable salt thereof.

12. (Presently Amended) A process for the preparation of a compound as defined in [any of claims 1-11] claim 1, which process comprises:

(a) reacting a compound of formula (II):




wherein R_1 , R_2 , R_3 , R_4 , m , p , X , --- , Y and D are as defined for formula (I), and L is a leaving group, with a compound of formula (III):



wherein Z is as defined for formula (I); or

(b) cyclising a compound of formula (IV):



wherein R_1 , R_2 , m , R_3 , p , R_4 , Y , D , Z and \equiv are as defined for formula (I) and G is a group $-X=CH_2$, wherein X is as defined for formula (I), dehydrogenated as required;

optionally followed by:

- removing any protecting groups; and/or
- converting a compound of formula (I) into another compound of formula (I); and/or
- forming a pharmaceutically acceptable salt.

13. (Presently Amended) A pharmaceutical composition comprising a compound as defined in [any of claims 1-14] claim 1 and a pharmaceutically acceptable carrier or excipient.

14. (Presently Amended) A process for preparing a pharmaceutical composition as defined in claim 13, the process comprising mixing a compound as defined in [any of claims 1-14] claim 1 and a pharmaceutically acceptable carrier or excipient.

15. (Presently Amended) A compound as defined in [any of claims 1-11] claim 1 for use as a therapeutic substance.

16. (Presently Amended) A compound as defined in [any of claims 1-11] claim 1 for use in the treatment of a CNS disorder.

17. (Presently Amended) A compound as defined in [any of claims 1-11] claim 1 for use in the treatment of depression or anxiety.

18. (Presently Amended) A method of treatment of a CNS disorder in a mammal including a human, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound as defined in [any of claims 1-11] claim 1.

19. (Presently Amended) A method of treatment of depression and or anxiety in a mammal including a human, which comprises administering to the sufferer a therapeutically safe and effective amount of a compound as defined in [any of claims 1-11] claim 1.

20. (Presently Amended) Use of a compound as defined in [any of claims 1-11] claim 1 in the manufacture of a medicament for use in the treatment of a CNS disorder.

21. (Presently Amended) The use of a compound as defined in [any of claims 1-11] claim 1 in the manufacture of a medicament for use in the treatment of depression or anxiety.